香蕉91成人一区二区三区飘花,91精品人妻一区二区三区蜜桃,四川少妇BBw搡BBBB槡BBBB,国产成人91一区二区三区APP
3358288340
CN
CN EN
Human Erythropoietin Injection(CHOCell)
EPOSINO is the first batch of recombinant human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, the Philippines and Indonesia.
Drug description

【Indications】

①Anemia caused by renal dysfunction, including dialysis and non-dialysis patients;

②Perioperative erythrocyte mobilization;

③Anemia caused by chemotherapy for non-myeloid malignancies. (To be added)


【R&D and Commercial Production of EPOSINO】

In 1991, technicians obtained the first batch of efficiently and stably expressed EPOengineered cell lines in China through genetic engineering technology, screening and various identifications;


In 1993, preclinical pilotscale production processes and preclinical animal trials were successfully completed in cooperation with relevant institutes, and various tests by the National Institute for the Control of Pharmaceutical and Biological Products were also passed;


In February 1994, the phase I clinical trial was approved by the Bureau of Drug Policy & Administration of Ministry of Health;


In January 1996, the phase II clinical trial was approved by the Bureau of Drug Policy & Administration of Ministry of Health;


In phase II clinical trial of EPOSINO, recombinant human erythropoietin originators (Epogen manufactured by Amgen in the USA, and Recormon manufactured by BoehrinMan in Germany) were used as reference substances in the pair therapy with EPOSINO. A total of 102 patients with anemia due to chronic renal failure were treated with EPOSINO. The efficacy was observed and compared: "The total effective rate of EPOSINO was 91.2%, and that of the original drug was 89.2%. The difference was not significant and the efficacy was equivalent" (data from the phase II clinical trial of EPOSINO).


In October 1996, the first new drug certificate issued by the Ministry of Health in China was obtained;


In October 1997, the first approval number for trial production in China was obtained;


In August 1998, the first approval number for formal production in China was obtained, and the new drug belonged to Class II biological products.


In 1999, the first prefilled syringe packaging was launch in China to facilitate clinical medication selection;


In 2006, clinical approval was obtained for the indication of perioperative erythrocyte mobilization;


In 2009, the albumin-free drug product was granted a patent for invention;


In 2011, the indication for perioperative erythrocyte mobilization was approved;


In 2013, supplementary approval was obtained for the albumin-free formulation;


In 2017, the clinical trial on the anemia indication of cancer chemotherapy was carried out;


In 2020, the marketing authorization application for the anemia indication of cancer chemotherapy was submitted;


Drug description
久久欧美性大无无码毛片 | 无码秘 蜜桃一区二区三区 无码人妻一区二区三区在线 | 国产电影一区二区三区 | 黄视频免费在线观看 | 国产成人无码精品久久 | 又粗又猛又爽又黄的视频 | 国产熟女丝袜喷水在线 | 四虎日本成人免费在线观看 | 亚洲无 码A片在线观看麻豆 | 91无码精品秘国产免多多 | 4444西西大胆无码视频 | 天天影视网天天综合色在线播放 | 国产精品人妻熟女毛片a 6 2v久 | 亚洲综合亚洲综合一区二区三区 | 搡老熟女大熟了一区二区 | 四季亚洲AV无码一区二区三匹在线观看 | 久久夜色精品国产欧美乱极品 | 草1024榴社区成人影院 | 又大又粗又黄又爽又明的黄片 | 国产一级婬乱片A片AAA图片 | 国产一级a毛一级a | 特级太黄A片老妇A片 | 中文字幕在线中文幕免费在线看免费版 | EEUSS秋霞鲁丝片无码 | 中文字幕一区二区三区乱码 | 天天日天天射天天干 | 农村黄艳一级A片 | 波多野结衣无码aV在线播放 | 少妇高潮免费看一级A片精东影视 | av无码专区在线观看成人 | 亚洲中文字幕在线观看 | 免费高清特级毛片A片微信群 | 人五月国外精品视频在线 | 91人妻人人澡人人爽人人 | 免费无遮挡无码永久在线观看视频 | 福利姬Jk丝袜-91Porn | 红桃视频网址永久在线 | 又大又粗又硬又爽又黄毛片视频 | 老熟妇一区二区三区啪啪 | 精品乱码一区内射人妻无码 | 影音先锋制服丝袜 |